Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC Infusion for Acute GVHD Prophylaxis and Treatment
NCT01941394Phase 2Unknown
- Sponsor
- National Medical Research Center for Hematology
- Start
- Oct 2007
- Primary completion
- Oct 2014
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mesenchymal stem cells in graft-versus-host disease (GVHD) (2 arms), sponsored by National Medical Research Center for Hematology. Primary endpoint: Graft-versus-host Disease at 1 year. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01941394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941394.